145 related articles for article (PubMed ID: 37740839)
1. A multivariate model based on gadoxetic acid-enhanced MRI using Li-RADS v2018 and other imaging features for preoperative prediction of dual‑phenotype hepatocellular carcinoma.
Liu MT; Zhang JY; Xu L; Qu Q; Lu MT; Jiang JF; Zhao XC; Zhang XQ; Zhang T
Radiol Med; 2023 Nov; 128(11):1333-1346. PubMed ID: 37740839
[TBL] [Abstract][Full Text] [Related]
2. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
[TBL] [Abstract][Full Text] [Related]
3. Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma.
Wu H; Liang Y; Wang Z; Tan C; Yang R; Wei X; Jiang X
Acta Radiol; 2023 Mar; 64(3):926-935. PubMed ID: 35898164
[TBL] [Abstract][Full Text] [Related]
4. Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.
Oh NE; Choi SH; Kim S; Lee H; Jang HJ; Byun JH; Won HJ; Shin YM
Eur Radiol; 2024 Jan; 34(1):465-474. PubMed ID: 37532900
[TBL] [Abstract][Full Text] [Related]
5. A gadoxetic acid-enhanced MRI-based model using LI-RADS v2018 features for preoperatively predicting Ki-67 expression in hepatocellular carcinoma.
Liang Y; Xu F; Mou Q; Wang Z; Xiao C; Zhou T; Zhang N; Yang J; Wu H
BMC Med Imaging; 2024 Jan; 24(1):27. PubMed ID: 38273242
[TBL] [Abstract][Full Text] [Related]
6. Radiomics for diagnosis of dual-phenotype hepatocellular carcinoma using Gd-EOB-DTPA-enhanced MRI and patient prognosis.
Huang X; Long L; Wei J; Li Y; Xia Y; Zuo P; Chai X
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2995-3003. PubMed ID: 31664520
[TBL] [Abstract][Full Text] [Related]
7. A gadoxetic acid-enhanced MRI-based multivariable model using LI-RADS v2018 and other imaging features for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma.
Liang Y; Xu F; Wang Z; Tan C; Zhang N; Wei X; Jiang X; Wu H
Eur J Radiol; 2022 Aug; 153():110356. PubMed ID: 35623312
[TBL] [Abstract][Full Text] [Related]
8. Comparison of CT and gadoxetic acid-enhanced MRI with liver imaging reporting and data system to assess liver tumors before resection.
Chen MF; Ho MC; Kao JH; Hwang RM; Deng SB; Yen KC; Liang PC; Wu CH
J Formos Med Assoc; 2024 Mar; 123(3):318-324. PubMed ID: 38044205
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Value of MRI Features in Dual-phenotype Hepatocellular Carcinoma: A Preliminary Study.
Gu HX; Huang XS; Xu JX; Zhu P; Xu JF; Fan SF
J Digit Imaging; 2023 Dec; 36(6):2554-2566. PubMed ID: 37578576
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma.
Kim SS; Lee S; Kim MJ
Eur Radiol; 2021 May; 31(5):3405-3416. PubMed ID: 33146795
[TBL] [Abstract][Full Text] [Related]
11. [The prediction value of enhanced magnetic resonance imaging nomogram model for dual phenotype hepatocellular carcinoma].
Wu Q; Yu YX; Fan YF; Hu S; Yao FR; Wang XM; Hu CH
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(15):1086-1092. PubMed ID: 35436807
[No Abstract] [Full Text] [Related]
12. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M
Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696
[TBL] [Abstract][Full Text] [Related]
13. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
[TBL] [Abstract][Full Text] [Related]
14. Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models.
Wu Q; Yu YX; Zhang T; Zhu WJ; Fan YF; Wang XM; Hu CH
J Magn Reson Imaging; 2023 Apr; 57(4):1185-1196. PubMed ID: 36190656
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI.
Ko A; Park HJ; Lee ES; Park SB; Kim YK; Choi SY; Ahn S
Clin Radiol; 2020 Apr; 75(4):319.e1-319.e9. PubMed ID: 31858990
[TBL] [Abstract][Full Text] [Related]
16. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
[TBL] [Abstract][Full Text] [Related]
17. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR
J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029
[TBL] [Abstract][Full Text] [Related]
18. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
[TBL] [Abstract][Full Text] [Related]
19. The role of gadoxetic acid-enhanced MRI features for predicting microvascular invasion in patients with hepatocellular carcinoma.
Yang H; Han P; Huang M; Yue X; Wu L; Li X; Fan W; Li Q; Ma G; Lei P
Abdom Radiol (NY); 2022 Mar; 47(3):948-956. PubMed ID: 34962593
[TBL] [Abstract][Full Text] [Related]
20. Long-term evolution of LR-2, LR-3 and LR-4 observations in HBV-related cirrhosis based on LI-RADS v2018 using gadoxetic acid-enhanced MRI.
Xing F; Zhang T; Miao X; Lu J; Du S; Jiang J; Xing W
Abdom Radiol (NY); 2023 Dec; 48(12):3703-3713. PubMed ID: 37740759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
